Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's

 
• By Jung Won Shin and Kosh Naran

Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.

Several Korean Firms Still In Parkinson’s Race • Source: Kosh Naran

More from South Korea

More from Focus On Asia